{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:14:03Z","timestamp":1769840043285,"version":"3.49.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T00:00:00Z","timestamp":1331769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11883-012-0239-y","type":"journal-article","created":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T09:35:56Z","timestamp":1331717756000},"page":"284-293","source":"Crossref","is-referenced-by-count":30,"title":["Liver X Receptors, Atherosclerosis and Inflammation"],"prefix":"10.1007","volume":"14","author":[{"given":"Daryn R.","family":"Michael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim G.","family":"Ashlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie L.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipak P.","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,15]]},"reference":[{"key":"239_CR1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbalip.2009.01.009","volume":"1791","author":"G Chinetti-Gbaguidi","year":"2009","unstructured":"Chinetti-Gbaguidi G, Staels B. Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. Biochim Biophys Acta. 2009;1791:486\u201393.","journal-title":"Biochim Biophys Acta"},{"key":"239_CR2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature07202","volume":"454","author":"SJ Bensinger","year":"2008","unstructured":"Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454:470\u20137.","journal-title":"Nature"},{"key":"239_CR3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.plipres.2010.03.002","volume":"49","author":"MH Oosterveer","year":"2010","unstructured":"Oosterveer MH, Grefhorst A, Groen AK, Kuipers F. The liver X receptor: control of cellular lipid homeostasis and beyond: implications for drug design. Prog Lipid Res. 2010;49:343\u201352.","journal-title":"Prog Lipid Res"},{"key":"239_CR4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/CIRCRESAHA.111.241810","volume":"109","author":"B Pourcet","year":"2011","unstructured":"Pourcet B, Feig JE, Vengrenyuk Y, et al. LXRalpha regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ Res. 2011;109:492\u2013501.","journal-title":"Circ Res"},{"key":"239_CR5","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.850400","volume":"14","author":"JR Schultz","year":"2000","unstructured":"Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14:2831\u20138.","journal-title":"Genes Dev"},{"key":"239_CR6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1074\/jbc.M605023200","volume":"282","author":"JY Cha","year":"2007","unstructured":"Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007;282:743\u201351.","journal-title":"J Biol Chem"},{"key":"239_CR7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1194\/jlr.M900096","volume":"51","author":"ED Bischoff","year":"2010","unstructured":"\u2022\u2022 Bischoff ED, Daige CL, Petrowski M, et al. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res. 2010;51:900\u20136. In contrast to numerous studies showing functional redundancy between LXR-\u03b1 and -\u03b2, this work, utilizing individual knockouts of LXR\u03b1 and LXR\u03b2 in the LDL receptor knockout background, shows that LXR\u03b1 plays a more selective role in limiting atherosclerosis in response to hyperlipidemia.","journal-title":"J Lipid Res"},{"key":"239_CR8","doi-asserted-by":"crossref","first-page":"43509","DOI":"10.1074\/jbc.M106155200","volume":"276","author":"KD Whitney","year":"2001","unstructured":"Whitney KD, Watson MA, Goodwin B, et al. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J Biol Chem. 2001;276:43509\u201315.","journal-title":"J Biol Chem"},{"key":"239_CR9","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1210\/en.2007-0150","volume":"148","author":"K Hashimoto","year":"2007","unstructured":"Hashimoto K, Matsumoto S, Yamada M, Satoh T, Mori M. Liver X receptor-alpha gene expression is positively regulated by thyroid hormone. Endocrinology. 2007;148:4667\u201375.","journal-title":"Endocrinology"},{"key":"239_CR10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.metabol.2006.10.007","volume":"56","author":"MS Kim","year":"2007","unstructured":"Kim MS, Sweeney TR, Shigenaga JK, et al. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism. 2007;56:267\u201379.","journal-title":"Metabolism"},{"key":"239_CR11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.atherosclerosis.2008.07.029","volume":"203","author":"XR Hao","year":"2009","unstructured":"Hao XR, Cao DL, Hu YW, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK\/STAT signaling pathway-dependent manner. Atherosclerosis. 2009;203:417\u201328.","journal-title":"Atherosclerosis"},{"key":"239_CR12","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1194\/jlr.M500157-JLR200","volume":"46","author":"M Chen","year":"2005","unstructured":"Chen M, Beaven S, Tontonoz P. Identification and characterization of two alternatively spliced transcript variants of human liver X receptor alpha. J Lipid Res. 2005;46:2570\u20139.","journal-title":"J Lipid Res"},{"key":"239_CR13","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbrc.2009.10.132","volume":"390","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K, Ishida E, Matsumoto S, et al. A liver X receptor (LXR)-beta alternative splicing variant (LXRBSV) acts as an RNA co-activator of LXR-beta. Biochem Biophys Res Commun. 2009;390:1260\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"239_CR14","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.febslet.2006.07.074","volume":"580","author":"M Chen","year":"2006","unstructured":"Chen M, Bradley MN, Beaven SW, Tontonoz P. Phosphorylation of the liver X receptors. FEBS Lett. 2006;580:4835\u201341.","journal-title":"FEBS Lett"},{"key":"239_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1677\/JOE-07-0525","volume":"197","author":"CJ Delvecchio","year":"2008","unstructured":"Delvecchio CJ, Capone JP. Protein kinase C alpha modulates liver X receptor alpha transactivation. J Endocrinol. 2008;197:121\u201330.","journal-title":"J Endocrinol"},{"key":"239_CR16","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/MCB.01575-07","volume":"28","author":"IP Torra","year":"2008","unstructured":"Torra IP, Ismaili N, Feig JE, et al. Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages. Mol Cell Biol. 2008;28:2626\u201336.","journal-title":"Mol Cell Biol"},{"key":"239_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1006\/bbrc.1998.8152","volume":"243","author":"CJ Huang","year":"1998","unstructured":"Huang CJ, Feltkamp D, Nilsson S, Gustafsson JA. Synergistic activation of RLD-1 by agents triggering PKA and PKC dependent signalling. Biochem Biophys Res Commun. 1998;243:657\u201363.","journal-title":"Biochem Biophys Res Commun"},{"key":"239_CR18","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.1074\/jbc.M611911200","volume":"282","author":"T Yamamoto","year":"2007","unstructured":"Yamamoto T, Shimano H, Inoue N, et al. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem. 2007;282:11687\u201395.","journal-title":"J Biol Chem"},{"key":"239_CR19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cellsig.2010.11.002","volume":"23","author":"EA Huwait","year":"2011","unstructured":"Huwait EA, Greenow KR, Singh NN, Ramji DP. A novel role for c-Jun N-terminal kinase and phosphoinositide 3-kinase in the liver X receptor-mediated induction of macrophage gene expression. Cell Signal. 2011;23:542\u20139.","journal-title":"Cell Signal"},{"key":"239_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.07.032","volume":"28","author":"X Li","year":"2007","unstructured":"Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell. 2007;28:91\u2013106.","journal-title":"Mol Cell"},{"key":"239_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2006.11.022","volume":"25","author":"S Ghisletti","year":"2007","unstructured":"Ghisletti S, Huang W, Ogawa S, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell. 2007;25:57\u201370.","journal-title":"Mol Cell"},{"key":"239_CR22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1074\/jbc.M109.082685","volume":"285","author":"EH Anthonisen","year":"2010","unstructured":"Anthonisen EH, Berven L, Holm S, Nygard M, Nebb HI, Gronning-Wang LM. Nuclear receptor liver X receptor is O-GlcNAc-modified in response to glucose. J Biol Chem. 2010;285:1607\u201315.","journal-title":"J Biol Chem"},{"key":"239_CR23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.plipres.2011.04.002","volume":"50","author":"JE McLaren","year":"2011","unstructured":"McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50:331\u201347.","journal-title":"Prog Lipid Res"},{"key":"239_CR24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2009.04.001","volume":"207","author":"F Morello","year":"2009","unstructured":"Morello F, Saglio E, Noghero A, et al. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis. 2009;207:38\u201344.","journal-title":"Atherosclerosis"},{"key":"239_CR25","doi-asserted-by":"crossref","first-page":"E339","DOI":"10.1152\/ajpendo.00022.2008","volume":"295","author":"A Peter","year":"2008","unstructured":"Peter A, Weigert C, Staiger H, et al. Induction of stearoyl-CoA desaturase protects human arterial endothelial cells against lipotoxicity. Am J Physiol Endocrinol Metab. 2008;295:E339\u201349.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"239_CR26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/ATVBAHA.107.143487","volume":"28","author":"M Zhu","year":"2008","unstructured":"Zhu M, Fu Y, Hou Y, et al. Laminar shear stress regulates liver X receptor in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:527\u201333.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"239_CR27","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1161\/01.RES.0000150368.56660.4f","volume":"95","author":"F Blaschke","year":"2004","unstructured":"Blaschke F, Leppanen O, Takata Y, et al. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res. 2004;95:e110\u201323.","journal-title":"Circ Res"},{"key":"239_CR28","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1210\/me.2007-0017","volume":"21","author":"CJ Delvecchio","year":"2007","unstructured":"Delvecchio CJ, Bilan P, Radford K, et al. Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol Endocrinol. 2007;21:1324\u201334.","journal-title":"Mol Endocrinol"},{"key":"239_CR29","doi-asserted-by":"crossref","first-page":"L949","DOI":"10.1152\/ajplung.90394.2008","volume":"295","author":"CJ Delvecchio","year":"2008","unstructured":"Delvecchio CJ, Bilan P, Nair P, Capone JP. LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1. Am J Physiol Lung Cell Mol Physiol. 2008;295:L949\u201357.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"239_CR30","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/HYPERTENSIONAHA.107.106963","volume":"51","author":"I Imayama","year":"2008","unstructured":"Imayama I, Ichiki T, Patton D, et al. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension. 2008;51:1631\u20136.","journal-title":"Hypertension"},{"key":"239_CR31","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/ATVBAHA.111.225383","volume":"31","author":"K Nakaya","year":"2011","unstructured":"\u2022 Nakaya K, Tohyama J, Naik SU, et al. Peroxisome proliferator-activated receptor-\u03b1 activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arterioscler Thromb Vasc Biol. 2011;31:1276\u201382. This study shows that a potent PPAR\u03b1 agonist stimulates reverse cholesterol transport in vivo through the PPAR\u03b1-LXR pathway.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"239_CR32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1097-2765(01)00164-2","volume":"7","author":"A Chawla","year":"2001","unstructured":"Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161\u201371.","journal-title":"Mol Cell"},{"key":"239_CR33","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/CIRCULATIONAHA.109.876839","volume":"121","author":"KY Lu","year":"2010","unstructured":"Lu KY, Ching LC, Su KH, et al. Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor alpha. Circulation. 2010;121:1828\u201337.","journal-title":"Circulation"},{"key":"239_CR34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/FJC.0b013e318167141f","volume":"51","author":"G Qiu","year":"2008","unstructured":"Qiu G, Hill JS. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J Cardiovasc Pharmacol. 2008;51:388\u201395.","journal-title":"J Cardiovasc Pharmacol"},{"key":"239_CR35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1161\/CIRCRESAHA.110.233775","volume":"108","author":"G Chinetti-Gbaguidi","year":"2011","unstructured":"\u2022\u2022 Chinetti-Gbaguidi G, Baron M, Bouhlel MA, et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPAR\u03b3 and LXR\u03b1 pathways. Circ Res. 2011;108:985\u201395. This study provides a link between LXRs and CD68(+) mannose receptor M2 macrophages seen in human atherosclerotic lesions. These macrophages have reduced capacity to handle and efflux choesterol because of low levels of LXR\u03b1 and its target genes.","journal-title":"Circ Res"},{"key":"239_CR36","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1194\/jlr.M700170-JLR200","volume":"48","author":"C Buono","year":"2007","unstructured":"Buono C, Li Y, Waldo SW, Kruth HS. Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL. J Lipid Res. 2007;48:2411\u20138.","journal-title":"J Lipid Res"},{"key":"239_CR37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1168974","volume":"325","author":"N Zelcer","year":"2009","unstructured":"\u2022\u2022 Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009;325:100\u20134. This study shows that LXRs also suppress LDL uptake via a novel pathway that involves transcriptional induction of the E3 ubiquitin ligase Idol (inducible degrader of the LDLR), which ubiquinates LDLR on its cytoplasmic domain, thereby targeting it for degradation. Adenoviral-mediated expression of Idol in mouse liver results in elevation of plasma LDL levels.","journal-title":"Science"},{"key":"239_CR38","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1161\/ATVBAHA.108.175042","volume":"28","author":"S Bultel","year":"2008","unstructured":"Bultel S, Helin L, Clavey V, et al. Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler Thromb Vasc Biol. 2008;28:2288\u201395.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"239_CR39","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/01.CIR.0000026802.79202.96","volume":"106","author":"GU Schuster","year":"2002","unstructured":"Schuster GU, Parini P, Wang L, et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation. 2002;106:1147\u201353.","journal-title":"Circulation"},{"key":"239_CR40","doi-asserted-by":"crossref","first-page":"11896","DOI":"10.1073\/pnas.182199799","volume":"99","author":"RK Tangirala","year":"2002","unstructured":"Tangirala RK, Bischoff ED, Joseph SB, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A. 2002;99:11896\u2013901.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"239_CR41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.105.560177","volume":"113","author":"SU Naik","year":"2006","unstructured":"Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113:90\u20137.","journal-title":"Circulation"},{"key":"239_CR42","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1128\/MCB.01469-10","volume":"31","author":"E Scotti","year":"2011","unstructured":"Scotti E, Hong C, Yoshinaga Y, et al. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol Cell Biol. 2011;31:1885\u201393.","journal-title":"Mol Cell Biol"},{"key":"239_CR43","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.112059299","volume":"99","author":"SB Joseph","year":"2002","unstructured":"Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99:7604\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"239_CR44","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1182\/blood-2010-09-306142","volume":"117","author":"M Spyridon","year":"2011","unstructured":"\u2022\u2022 Spyridon M, Moraes LA, Jones CI, et al. LXR as a novel antithrombotic target. Blood. 2011;117:5751\u201361. This report demonstrates LXRs as novel antithrombotic targets. LXR agonists were found to inhibit platelet aggregation by a range of agonists and reduced the size and stability of thrombi in an in vivo model of thrombosis in mice.","journal-title":"Blood"},{"key":"239_CR45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(02)03578-0","volume":"536","author":"N Terasaka","year":"2003","unstructured":"Terasaka N, Hiroshima A, Koieyama T, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 2003;536:6\u201311.","journal-title":"FEBS Lett"},{"key":"239_CR46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.ATV.0000178996.91277.fb","volume":"25","author":"N Levin","year":"2005","unstructured":"Levin N, Bischoff ED, Daige CL, et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol. 2005;25:135\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"239_CR47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1194\/jlr.M800374-JLR200","volume":"50","author":"L Verschuren","year":"2009","unstructured":"\u2022 Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J Lipid Res. 2009;50:301\u201311. This study shows that LXR agonists not only suppress atherosclerotic lesion growth but also promote lesion regression.","journal-title":"J Lipid Res"},{"key":"239_CR48","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1172\/JCI38911","volume":"120","author":"JE Feig","year":"2010","unstructured":"Feig JE, Pineda-Torra I, Sanson M, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest. 2010;120:4415\u201324.","journal-title":"J Clin Invest"},{"key":"239_CR49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/ATVBAHA.107.158998","volume":"28","author":"E Rigamonti","year":"2008","unstructured":"Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol. 2008;28:1050\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"239_CR50","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/en.143.7.2548","volume":"143","author":"JG Menke","year":"2002","unstructured":"Menke JG, Macnaul KL, Hayes NS, et al. A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002;143:2548\u201358.","journal-title":"Endocrinology"},{"key":"239_CR51","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/ATVBAHA.109.194548","volume":"29","author":"S Larrede","year":"2009","unstructured":"Larrede S, Quinn CM, Jessup W, et al. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol. 2009;29:1930\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"239_CR52","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1476-5381.2011.01202.x","volume":"162","author":"D Peng","year":"2011","unstructured":"\u2022 Peng D, Hiipakka RA, Xie JT, et al. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-\/-) mice. Br J Pharmacol. 2011;162:1792\u2013804. A recent study demonstrating the efficacy of novel LXR agonists (ATI-111 in this case) that significantly attenuate atherosclerosis in mouse model systems without inducing fatty liver and hypertriglyceridemia.","journal-title":"Br J Pharmacol"},{"key":"239_CR53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1194\/jlr.M800376-JLR200","volume":"50","author":"A Kratzer","year":"2009","unstructured":"Kratzer A, Buchebner M, Pfeifer T, et al. Synthetic LXR agonist attenuates plaque formation in apoE-\/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res. 2009;50:312\u201326.","journal-title":"J Lipid Res"},{"key":"239_CR54","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/jpet.108.142687","volume":"327","author":"D Peng","year":"2008","unstructured":"Peng D, Hiipakka RA, Dai Q, et al. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther. 2008;327:332\u201342.","journal-title":"J Pharmacol Exp Ther"},{"key":"239_CR55","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1476-5381.2010.01168.x","volume":"162","author":"J Hoorn van der","year":"2011","unstructured":"van der Hoorn J, Lind\u00e9n D, Lindahl U, et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol. 2011;162:1553\u201363.","journal-title":"Br J Pharmacol"},{"key":"239_CR56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000321320","volume":"86","author":"W Yan","year":"2010","unstructured":"Yan W, Zhang T, Cheng J, Zhou X, Qu X, Hu H. Liver X receptor agonist methyl-3\u03b2-hydroxy-5\u03b1,6\u03b1-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. Pharmacology. 2010;86:306\u201312.","journal-title":"Pharmacology"},{"key":"239_CR57","doi-asserted-by":"crossref","unstructured":"\u2022 Giannarelli C, Cimmino G, Connolly TM, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. 2011;33:264\u201373. doi: 10.1093\/eurheartj\/ehr136 . This study demonstrates the potential of combination therapy (LXR agonist and statins in this case) in the treatment of atherosclerosis.","DOI":"10.1093\/eurheartj\/ehr136"},{"key":"239_CR58","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1194\/jlr.M900037-JLR200","volume":"50","author":"EM Quinet","year":"2009","unstructured":"Quinet EM, Basso MD, Halpern AR, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res. 2009;50:2358\u201370.","journal-title":"J Lipid Res"},{"key":"239_CR59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1479-5876-6-59","volume":"6","author":"EA DiBlasio-Smith","year":"2008","unstructured":"DiBlasio-Smith EA, Arai M, Quinet EM, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med. 2008;6:59.","journal-title":"J Transl Med"},{"key":"239_CR60","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1172\/JCI31909","volume":"117","author":"MN Bradley","year":"2007","unstructured":"Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest. 2007;117:2337\u201346.","journal-title":"J Clin Invest"},{"key":"239_CR61","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/mol.106.022608","volume":"70","author":"EM Quinet","year":"2006","unstructured":"Quinet EM, Savio DA, Halpern AR, et al. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting. Mol Pharmacol. 2006;70:1340\u20139.","journal-title":"Mol Pharmacol"},{"key":"239_CR62","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1124\/jpet.108.143271","volume":"327","author":"R Mukherjee","year":"2008","unstructured":"Mukherjee R, Locke KT, Miao B, et al. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther. 2008;327:716\u201326.","journal-title":"J Pharmacol Exp Ther"},{"key":"239_CR63","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1161\/ATVBAHA.108.175257","volume":"28","author":"D Teupser","year":"2008","unstructured":"Teupser D, Kretzschmar D, Tennert C, et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:2009\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"239_CR64","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/gt.2011.29","volume":"18","author":"G Li","year":"2011","unstructured":"Li G, Biju KC, Xu X, et al. Macrophage LXR\u03b1 gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-\/-) mice. Gene Ther. 2011;18:835\u201341.","journal-title":"Gene Ther"},{"key":"239_CR65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1194\/jlr.M700571-JLR200","volume":"50","author":"JF Rippmann","year":"2009","unstructured":"Rippmann JF, Schoelch C, Nolte T, et al. Improved lipid profile through liver-specific knockdown of liver X receptor alpha in KKAy diabetic mice. J Lipid Res. 2009;50:22\u201331.","journal-title":"J Lipid Res"},{"key":"239_CR66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2010.07.002","volume":"12","author":"G Lo Sasso","year":"2010","unstructured":"\u2022\u2022 Lo Sasso G, Murzilli S, Salvatore L, et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metabol. 2010;12:187\u201393. This study demonstrates that intestinal-specific LXR activation reduces intestinal cholesterol absorption, improves lipoprotein profile, increases reverse cholesterol transport in vivo, and protects against atherosclerosis in a mouse model system.","journal-title":"Cell Metabol"},{"key":"239_CR67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm820","volume":"9","author":"SB Joseph","year":"2003","unstructured":"Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213\u20139.","journal-title":"Nat Med"},{"key":"239_CR68","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jnr.21038","volume":"84","author":"C Hindinger","year":"2006","unstructured":"Hindinger C, Hinton DR, Kirwin SJ, et al. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J Neurosci Res. 2006;84:1225\u201334.","journal-title":"J Neurosci Res"},{"key":"239_CR69","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1073\/pnas.0701096104","volume":"104","author":"N Zelcer","year":"2007","unstructured":"Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer\u2019s disease pathology by liver x receptors. Proc Natl Acad Sci U S A. 2007;104:10601\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"239_CR70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.immuni.2009.06.018","volume":"31","author":"N A-Gonzalez","year":"2009","unstructured":"A-Gonzalez N, Bensinger SJ, Hong C, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 2009;31:245\u201358.","journal-title":"Immunity"},{"key":"239_CR71","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2006.11.007","volume":"183","author":"CX Zhang-Gandhi","year":"2007","unstructured":"Zhang-Gandhi CX, Drew PD. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J Neuroimmunol. 2007;183:50\u20139.","journal-title":"J Neuroimmunol"},{"key":"239_CR72","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.108.782300","volume":"118","author":"JR Morales","year":"2008","unstructured":"Morales JR, Ballesteros I, Deniz JM, et al. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation. 2008;118:1450\u20139.","journal-title":"Circulation"},{"key":"239_CR73","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1172\/JCI35288","volume":"119","author":"H Korf","year":"2009","unstructured":"Korf H, Vander Beken S, Romano M, et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J Clin Invest. 2009;119:1626\u201337.","journal-title":"J Clin Invest"},{"key":"239_CR74","doi-asserted-by":"crossref","first-page":"e1000981","DOI":"10.1371\/journal.ppat.1000981","volume":"6","author":"TM Hanley","year":"2010","unstructured":"Hanley TM, Blay Puryear W, Gummuluru S, Viglianti GA. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog. 2010;6:e1000981.","journal-title":"PLoS Pathog"},{"key":"239_CR75","doi-asserted-by":"crossref","first-page":"32197","DOI":"10.1074\/jbc.M605237200","volume":"281","author":"C Marathe","year":"2006","unstructured":"Marathe C, Bradley MN, Hong C, et al. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. J Biol Chem. 2006;281:32197\u2013206.","journal-title":"J Biol Chem"},{"key":"239_CR76","doi-asserted-by":"crossref","first-page":"10443","DOI":"10.1074\/jbc.M213071200","volume":"278","author":"A Castrillo","year":"2003","unstructured":"Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem. 2003;278:10443\u20139.","journal-title":"J Biol Chem"},{"key":"239_CR77","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1161\/01.RES.0000163630.86796.17","volume":"96","author":"D Ogawa","year":"2005","unstructured":"Ogawa D, Stone JF, Takata Y, et al. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res. 2005;96:e59\u201367.","journal-title":"Circ Res"},{"key":"239_CR78","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/01.RES.0000252878.34269.06","volume":"99","author":"F Blaschke","year":"2006","unstructured":"Blaschke F, Takata Y, Caglayan E, et al. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res. 2006;99:e88\u201399.","journal-title":"Circ Res"},{"key":"239_CR79","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1101\/gad.545110","volume":"24","author":"N Venteclef","year":"2010","unstructured":"\u2022\u2022 Venteclef N, Jakobsson T, Ehrlund A, et al. GPS2-dependent corepressor\/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 2010;24:381\u201395. This study provides mechanistic insight into the anti-inflammatory actions of LXRs in the hepatic acute phase response (APR). The work demonstrates that the anti-inflammatory actions of LXR agonists are mediated selectively by LXR\u03b2 and involve SUMOylation-dependent recruitment of the nuclear receptor to hepatic APR promoters leading to the prevention of clearance of NCoR complex.","journal-title":"Genes Dev"},{"key":"239_CR80","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1101\/gad.1773109","volume":"23","author":"S Ghisletti","year":"2009","unstructured":"\u2022\u2022 Ghisletti S, Huang W, Jepsen K, et al. Cooperative NCoR\/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009;23:681\u201393. This study provides molecular insight into the mechanisms underlying transrepression of a large cohort of inflammatory genes and demonstrates that NCoR and SMRT corepressors are required for nearly all the transrepression activities of LXRs.","journal-title":"Genes Dev"},{"key":"239_CR81","doi-asserted-by":"crossref","unstructured":"\u2022 Huang W, Ghisletti S, Perissi V, Rosenfeld MG, Glass CK. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR derepression checkpoint. Mol Cell. 2009;3548\u201357. This report shows that a pathway in which TLR4 uses NF\u03baB to deliver IKK\u03b5 to target gene promoters containing \u03baB and AP1 sites and leads to the phosphorylation of c-Jun, and the clearance of the NCoR complex is sensitive to transrepression by LXRs.","DOI":"10.1016\/j.molcel.2009.05.023"},{"key":"239_CR82","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nature09703","volume":"470","author":"W Huang","year":"2011","unstructured":"\u2022\u2022 Huang W, Ghisletti S, Saijo K, et al. Coronin 2A mediates actin-dependent de-repression of inflammatory response genes. Nature. 2011, 470:414\u20138. This work identifies a coronin 2A-actin dependent mechanism for the de-repression of inflammatory genes and provides insight on how post-translational modification of LXR in response to inflammatory signals can impact its transrepression activity.","journal-title":"Nature"},{"key":"239_CR83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cytogfr.2008.11.003","volume":"20","author":"J McLaren","year":"2009","unstructured":"McLaren J, Ramji DP. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2009;20:125\u201335.","journal-title":"Cytokine Growth Factor Rev"},{"key":"239_CR84","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jcb.22976","volume":"112","author":"N Li","year":"2010","unstructured":"Li N, Salter RC, Ramji DP. Molecular mechanisms underlying the inhibition of IFN-gamma-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem. 2010;112:675\u201383.","journal-title":"J Cell Biochem"},{"key":"239_CR85","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.molcel.2009.07.021","volume":"35","author":"JH Lee","year":"2009","unstructured":"\u2022 Lee JH, Park SM, Kim OS, et al. Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol Cell. 2009;35:806\u201317. This work demonstrates that LXR ligands inhibit STAT1 binding to target gene promoters and provides insight into the mechanisms underlying transrepression by LXRs through STAT1.","journal-title":"Mol Cell"},{"key":"239_CR86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCRESAHA.106.135814","volume":"101","author":"C Fontaine","year":"2007","unstructured":"Fontaine C, Rigamonti E, Nohara A, et al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res. 2007;101:40\u20139.","journal-title":"Circ Res"},{"key":"239_CR87","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/art.24717","volume":"60","author":"DL Asquith","year":"2009","unstructured":"Asquith DL, Miller AM, Hueber AJ, et al. Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum. 2009;60:2655\u201365.","journal-title":"Arthritis Rheum"},{"key":"239_CR88","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.4049\/jimmunol.0902399","volume":"184","author":"D Torocsik","year":"2010","unstructured":"Torocsik D, Barath M, Benko S, et al. Activation of liver X receptor sensitizes human dendritic cells to inflammatory stimuli. J Immunol. 2010;184:5456\u201365.","journal-title":"J Immunol"},{"key":"239_CR89","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","volume":"477","author":"JH Choi","year":"2011","unstructured":"Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature. 2011;477:477\u201381.","journal-title":"Nature"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-012-0239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-012-0239-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-012-0239-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T07:50:22Z","timestamp":1561449022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-012-0239-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,15]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s11883-012-0239-y","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,15]]}}}